泰达生物(08189)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

08189 泰达生物

休市中 08-21 09:00:00

0.270

+0.000

0.00%

最高0.270	最低0.270	成交量0.00
今开0.270	昨收0.270	日振幅0.00%
总市值5.76亿	流通市值3.88亿	总股本21.34亿
成交额0.00	换手率0.00%	流通股本14.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"08189","market":"HK","secType":"STK","nameCN":"泰达生物","latestPrice":0.27,"timestamp":1787274000018,"preClose":0.27,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":1436400000,"shares":2134000000,"eps":-0.0509435086196759,"marketStatus":"休市中","change":0,"latestTime":"08-21 09:00:00","open":0.27,"high":0.27,"low":0.27,"amount":0,"amplitude":0,"askPrice":0.27,"askSize":90000,"bidPrice":0.255,"bidSize":200000,"shortable":0,"etf":0,"ttmEps":-0.0509435086196759,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1024329600000,"exchange":"SEHK","adjPreClose":0.27,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0,"lotSize":5000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/08189/wiki","defaultTab":"wiki","newsList":[{"id":"2660451410","title":"泰达生物(08189)发盈喜 预期中期股东应占净利润约700万元至1000万元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2660451410","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660451410?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:52","pubTimestamp":1787028721,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物(08189)发布公告，截至2026年6月30日止6个月集团预期取得：收入约人民币2.9亿元至人民币3亿元，较截至2025年6月30日止6个月(去年同期)的收入约人民币2.26亿元，增加约28%至33%;及公司拥有人应占净利润约人民币700万元至人民币1000万元，较去年同期公司拥有人应占亏损约人民币600万元，增加约209%至256%, 实现扭亏为盈。报告期内收入及公司拥有人应占净利润增长主要来自于AI生命健康业务的快速扩展。报告期内AI生命健康业务取得收入约人民币1亿元至人民币1.1亿元，公司拥有人应占净利润约人民币1000万元到1200万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143888517","title":"泰达生物（08189）发盈喜：2026年上半年预盈最高1,000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143888517","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143888517?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:31","pubTimestamp":1787027479,"startTime":"0","endTime":"0","summary":"2026年8月18日，泰达生物公布盈利预告，预计截至2026年6月30日止六个月实现收入约2.9亿元至3亿元，较去年同期的2.26亿元增长约28%至33%。同期，公司预计录得归属于本公司股东的净利润约700万元至1,000万元，而去年同期为亏损约600万元，增幅约209%至256%，实现扭亏为盈。公司表示，上述数据基于未经审计的综合管理账目及董事会现有资料作出的初步评估，最终结果可能有所调整。泰达生物计划于2026年8月31日发布正式中期业绩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192730897","title":"泰达生物预计2026年上半年净利润达700万至1000万元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1192730897","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192730897?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:27","pubTimestamp":1787027229,"startTime":"0","endTime":"0","summary":"泰达生物（Tianjin TEDA Biomedical Engineering Co）于今日发布公告，预期截至2026年6月30日止六个月将录得净利润介于700万元至1000万元人民币之间。这一业绩预告揭示了公司在近期经营活动中展现出的积极态势，尽管市场环境仍充满变数，但管理层对未来盈利能力抱持审慎乐观态度。值得注意的是，该预期数字反映了公司在成本控制与业务拓展方面所做出的持续努力，同时也暗示了行业复苏迹象初现端倪。不过，最终财务数据仍需以正式披露的中期报告为准，投资者应保持理性判断，密切关注后续公告详情。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189","BK1113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189784429","title":"泰达生物预期2026年上半年营收达2.9亿至3亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1189784429","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189784429?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:27","pubTimestamp":1787027228,"startTime":"0","endTime":"0","summary":"泰达生物（TEDA BIOMEDICAL）发布公告，预计截至2026年6月30日止六个月的营业收入将在2.9亿元人民币至3亿元人民币之间。这一预期反映了公司在生物医学工程领域持续拓展的积极态势，尽管市场环境复杂多变，公司仍展现出稳健的经营韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189","BK1113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107915885","title":"泰达生物（08189）拟于8月31日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1107915885","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107915885?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:42","pubTimestamp":1786696960,"startTime":"0","endTime":"0","summary":"泰达生物8月14日公告，公司董事会将于2026年8月31日10时在中国天津市天津经济技术开发区第四大街80号天大科技园A2座第9层召开董事会会议。\\n\\n根据GEM上市规则，本公告自刊发日期起至少连续七日于GEM网站及公司官网公开披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153845367","title":"泰达生物2026年7月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1153845367","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153845367?lang=zh_cn&edition=full","pubTime":"2026-08-03 11:46","pubTimestamp":1785728784,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司于2026年8月3日发布截至2026年7月31日的证券变动月报表。公告显示，公司本期没有新增股份发行、股份购回或注销等变动行为。公司披露，截至2026年7月31日，普通股H股注册股本维持1,436,400,000股，每股面值人民币0.1元，注册股本为人民币143,640,000元；内资股注册股本维持697,500,000股，每股面值人民币0.1元，注册股本为人民币69,750,000元。公告还显示，公司目前符合香港联交所对于股本及公众持股量的相关要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137702370","title":"泰达生物6月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1137702370","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137702370?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:28","pubTimestamp":1783074520,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司于2026年7月3日发布了截至2026年6月30日的月度股份变动报告，披露了公司在报告期内的股本结构与股份变动情况。报告显示，截至2026年6月30日，公司法定注册股本为人民币213,390,000元，股本结构维持不变，其中包括1,436,400,000股H股，以及697,500,000股内资股。本月内，公司已发行股份与库藏股份总数均未发生变化：H股、内资股数目分别保持1,436,400,000股及697,500,000股，未发生股票发行、购回、注销或库藏股变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184275716","title":"泰达生物更新2026年5月股份变动月报表 股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1184275716","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184275716?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:42","pubTimestamp":1780479775,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司于2026年06月03日发布2026年5月的股份变动月报表，覆盖2026年5月1日至5月31日期间公司股份状况。月报显示，泰达生物在本报告期内未进行任何新增股份发行或股本减少，也无股份回购、注销或库藏股操作。泰达生物在公告中确认公司已充分满足香港联交所的最低公众持股量要求，并表示上述事项均已履行相关法律法规以及香港联交所《上市规则》的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172418586","title":"泰达生物更新4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1172418586","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172418586?lang=zh_cn&edition=full","pubTime":"2026-05-04 10:02","pubTimestamp":1777860125,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司于2026年5月4日发布截至2026年4月30日的股份变动月报表。报告显示，公司当月未进行新增股份发行、购回或注销，整体股本结构保持稳定。根据公告，泰达生物截至2026年4月30日的注册股本总额为人民币213,390,000元，较上月无变化。报告期内，泰达生物未发生任何与股份期权计划或股权激励相关的股份授予、行使及失效事宜，也未进行任何形式的股份回购或注销操作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165977439","title":"泰达生物（08189）2025年营收上升35.68%，多元化业务并行下亏损扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1165977439","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165977439?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:21","pubTimestamp":1777551696,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司公布截至2025年12月31日止年度主要经营和财务情况，显示整体收入显著增长，但亏损幅度有所扩大。公司业务主要聚焦肥料产品和AI生命健康两大板块，持续推进产业链整合及跨领域协同。每股亏损由2024年度的人民币1.46分上升至4.37分。资产负债方面，截至2025年12月31日，资产总额约人民币2.65亿元，负债总额约人民币2.62亿元，股东应占权益约人民币1,222.4万元，较上年同期有所下滑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"泰达生物（08189）2025年营收上升35.68%，多元化业务并行下亏损扩大","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631632386","title":"泰达生物(08189)：夏瑞哲调任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2631632386","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631632386?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:18","pubTimestamp":1777551516,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物(08189)发布公告，公司执行董事夏瑞哲先生因受其持有的香港证券及期货事务监察委员会9号资产管理人RO牌照相关监管限制，申请由公司执行董事调任为非执行董事。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1113","08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173850069","title":"泰达生物3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1173850069","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173850069?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:17","pubTimestamp":1775042240,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司于2026年4月1日发布3月股份变动月报表，报告期截至2026年3月31日。根据公告披露，公司当月各类股份及注册股本均无新增发行或注销情况。公司同时确认当月无回购或库藏股行动，也未发生任何股份期权、权证或可换股票据的变动。公司在公告中声明，已遵守香港联合交易所有限公司《上市规则》及其他相关法律规定，并由董事孙莉签署确认。综上所述，截至3月31日，泰达生物股本结构保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624364075","title":"泰达生物(08189)：Lynn Li获委任为公司联席行政总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2624364075","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624364075?lang=zh_cn&edition=full","pubTime":"2026-04-01 00:22","pubTimestamp":1774974159,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物(08189)发布公告，Lynn Li女士已获委任为公司联席行政总裁及孙莉女士已由公司的行政总裁调任为公司的联席行政总裁，自2026年3月31日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["08189","BK1113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624536528","title":"泰达生物(08189)发布年度业绩 股东应占亏损9082万元 同比扩大226.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624536528","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624536528?lang=zh_cn&edition=full","pubTime":"2026-04-01 00:10","pubTimestamp":1774973418,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物(08189)发布截至2025年12月31日止年度业绩，集团营业额人民币5.23亿元，同比增长35.67%;股东应占亏损9082万元，同比扩大226.67%;每股亏损4.37分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"泰达生物(08189)发布年度业绩 股东应占亏损9082万元 同比扩大226.67%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1113","08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191221420","title":"泰达生物(08189.HK)任命李琳为联席首席执行官 孙莉再度获委任联席CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=1191221420","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191221420?lang=zh_cn&edition=full","pubTime":"2026-03-31 22:21","pubTimestamp":1774966873,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司宣布，公司已正式任命李琳为联席首席执行官，与孙莉共同担任公司最高管理职务。同时，孙莉亦再度获委任为联席首席执行官，继续发挥其领导作用。\n此次管理层调整旨在优化公司治理结构，强化战略执行能力。李琳的加入将为公司带来新的管理视角和行业经验，而孙莉的连任则确保了领导团队的连续性和稳定性。这一人事安排体现了公司对业务发展和管理效能的双重重视，有望为泰达生物的未来发展注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1113","08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120096620","title":"泰达生物：预计2025年度股东应占亏损扩大至约8,500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120096620","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120096620?lang=zh_cn&edition=full","pubTime":"2026-03-29 18:11","pubTimestamp":1774779099,"startTime":"0","endTime":"0","summary":"泰达生物29日发布盈利警告称，预计截至2025年12月31日止年度将录得约8,500万元人民币的股东应占亏损，而上一财年公司录得亏损2,780.22万元人民币。按可比口径计算，本年度亏损规模预计同比扩大约205%。公告同时提示，相关数据基于董事会对集团截至报告期业绩的初步评估，最终经审计结果可能有所调整。公司计划于2026年3月底前披露经审核的2025年度业绩。泰达生物建议投资者及股东在买卖公司股份时保持审慎，并关注后续公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623353708","title":"泰达生物(08189)发盈警 预计年度股东应占亏损约8500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623353708","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2623353708?lang=zh_cn&edition=full","pubTime":"2026-03-29 18:10","pubTimestamp":1774779038,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物(08189)发布公告，本集团预计截至2025年12月31日止年度将录得股东应占亏损约8500万元人民币，而2024年12月31日止年度股东应占亏损为2780.22万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"泰达生物(08189)发盈警 预计年度股东应占亏损约8500万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["08189","BK1113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618133203","title":"泰达生物盘中异动 快速跳水6.67%报0.280港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618133203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618133203?lang=zh_cn&edition=full","pubTime":"2026-03-12 10:04","pubTimestamp":1773281050,"startTime":"0","endTime":"0","summary":"2026年03月12日早盘10时04分，泰达生物股票出现波动，股价快速下挫6.67%。截至发稿，该股报0.280港元/股，成交量26.5万股，换手率0.02%，振幅5.00%。资金方面，该股资金流入1.885万港元，流出5.225万港元。泰达生物股票所在的化肥农药行业中，整体涨幅为0.02%。其相关个股中，中海石油化学、大成生化科技、中化化肥涨幅较大，振幅较大的相关个股有中海石油化学、大成生化科技、泰达生物，振幅分别为7.01%、6.56%、5.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312100410a4628e02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312100410a4628e02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["08189","BK1113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199896242","title":"天津泰达生物医学工程（08189）2026年2月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1199896242","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199896242?lang=zh_cn&edition=full","pubTime":"2026-03-02 10:25","pubTimestamp":1772418334,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司于2026年3月2日发布2026年2月股份变动月报表。公告显示，公司注册股本及已发行股份在当月保持不变。合计已发行股份总数2,133,900,000股，面值均为每股人民币0.1元。公告披露，2026年2月期间公司未进行新增发行、购回、注销或任何库藏股变动；同时未有任何股份期权、可换股票据或其他发行人股份相关权证与协议发生变动。公告由公司董事孙莉签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613737865","title":"泰达生物盘中异动 大幅下跌6.25%报0.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613737865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2613737865?lang=zh_cn&edition=full","pubTime":"2026-02-23 10:04","pubTimestamp":1771812266,"startTime":"0","endTime":"0","summary":"2026年02月23日早盘10时04分，泰达生物股票出现波动，股价快速下挫6.25%。截至发稿，该股报0.300港元/股，成交量31万股，换手率0.02%，振幅6.25%。资金方面，该股资金流入3100港元，流出3.8125万港元。泰达生物股票所在的化肥农药行业中，整体涨幅为0.05%。其相关个股中，玖源集团、中化化肥、米高集团涨幅较大，振幅较大的相关个股有玖源集团、泰达生物、中国心连心化肥，振幅分别为111.76%、3.13%、2.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022310042697a6afd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022310042697a6afd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1113","08189"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioteda.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.8621},{"period":"3month","weight":0.2558},{"period":"6month","weight":-0.1562},{"period":"1year","weight":-0.4194},{"period":"ytd","weight":-0.1148}],"compareEarnings":[{"period":"1week","weight":0.0355},{"period":"1month","weight":0.0449},{"period":"3month","weight":0.0158},{"period":"6month","weight":-0.0153},{"period":"1year","weight":0.036},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"天津泰达生物医学工程股份有限公司是一家主要从事生物复合肥料产品的制造及销售的中国公司。该公司主要通过两个分部运营其业务。肥料产品分部从事制造及销售生物复合肥料产品（包括活性肥、不同配方的氮、磷及钾复合肥）、提供仓储服务以及肥料产品的加工及许可。养老及保健服务分部从事提供综合养老及保健服务，包括租赁老年人设备。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.541667,"avgChangeRate":0.014438},{"month":2,"riseRate":0.541667,"avgChangeRate":-0.007724},{"month":3,"riseRate":0.458333,"avgChangeRate":0.035341},{"month":4,"riseRate":0.208333,"avgChangeRate":0.000187},{"month":5,"riseRate":0.5,"avgChangeRate":0.09602},{"month":6,"riseRate":0.375,"avgChangeRate":-0.018794},{"month":7,"riseRate":0.4,"avgChangeRate":-0.025235},{"month":8,"riseRate":0.64,"avgChangeRate":0.194271},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.003149},{"month":10,"riseRate":0.208333,"avgChangeRate":-0.065134},{"month":11,"riseRate":0.291667,"avgChangeRate":0.035483},{"month":12,"riseRate":0.25,"avgChangeRate":0.00692}],"exchange":"SEHK","name":"泰达生物","nameEN":"TEDA BIOMEDICAL"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰达生物(08189)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰达生物(08189)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰达生物,08189,泰达生物股票,泰达生物股票老虎,泰达生物股票老虎国际,泰达生物行情,泰达生物股票行情,泰达生物股价,泰达生物股市,泰达生物股票价格,泰达生物股票交易,泰达生物股票购买,泰达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰达生物(08189)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰达生物(08189)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}